IN8bio, Inc. (INAB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IN8bio, Inc. on February 27, 2026, covering events occurring on February 26, 2026. The Company is a Delaware corporation with its principal executive offices in New York, New York, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "INAB".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: Alan S. Roemer resigned as a director and as a member of the Audit and Compensation Committees, effective February 28, 2026.
- Reason for Departure: The resignation was not the result of any disagreement with the Company, its management, or the Board regarding operations, policies, or practices.
- Board Appointment: Jeremy Graff, an independent director, was appointed as Interim Chair of the Board, effective February 28, 2026.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Confirm the effective date of Alan S. Roemer's resignation (February 28, 2026).
- Verify the appointment of Jeremy Graff as Interim Chair of the Board.
- Review the composition of the Audit and Compensation Committees following Mr. Roemer's departure to ensure quorum and compliance.
- Check for any subsequent filings regarding the permanent replacement for the Chair position or the vacant director seat.